Drug Profile


Alternative Names: PF-05208769; SCA-136; Vabicaserin hydrochloride

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Antipsychotics
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bipolar disorders; Schizophrenia

Most Recent Events

  • 10 May 2012 Discontinued - Phase-I for Schizophrenia in USA (PO)
  • 27 Jan 2010 Phase-I clinical trials in Schizophrenia in USA (PO)
  • 31 Dec 2009 Discontinued - Phase-II for Bipolar disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top